Vol 8, Supplement 5 (July 10, 2016): Journal of Thoracic Disease (Impact and Influence of Real-Life Respiratory Research - Abstracts from the Respiratory Effectiveness Group 2016 Summit)

Meeting Highlights

2016 Respiratory Effectiveness Group Annual Summit Report—impact & influence of real-world respiratory evidence
Alison Chisholm, Nemr Eid, Bernardino Alcázar-Navarrete, Aji Barot, George Christoff, David B. Price


AB014. Effect of beta-blockers on the risk of COPD exacerbations
Lies Lahousse, Phebe De Nocker, A. Hofman, Bruno H. Stricker, Guy G. Brusselle, Katia M. C. Verhamme
AB022. Validity of the five-level new version of the EQ-5D in asthma patients
Gimena Hernandez, Àngels Pont, Olatz Garin, Marc Martí, Jordi Alonso, Eric Van Ganse, Laurent Laforest, Alexandra L. Dima, Marijn de Bruin, Montserrat Ferrer, the ASTRO-LAB group
AB030. Prevalence and incidence of bronchiectasis in Catalonia in 2012
Mònica Monteagudo, Teresa Rodriguez, Miriam Barrecheguren, Pere Simonet, Marc Miravitlles
AB038. Pragmatic trial comparing continuing Seretide® MDI with changing to Flutiform® in asthma
Anu Kemppinen, Elizabeth Gardener, Vicky Thomas, Priyanka Raju, Christina Callan, Andrew McLoughlin, Vanessa Woodhead, Adam Brady, Elizabeth F. Juniper, Peter J. Barnes, Omar S. Usmani, David Price
AB015. Current diagnostic approaches in ILD: ILD vs. non-specialty clinics
Elizabeth Belloli, Michael Rosenbluth, Yoonha Choi, Sherry Danese, Pauline Bianchi, Fernando Martinez, Kevin Flaherty
AB023. Validity of the EQ-5D-Youth in asthmatic children
Gimena Hernandez, Monica Avila, Olatz Garin, Pont Àngels, Montserrat Ferrer, on behalf of the ASTRO-LAB group
AB031. Validation of claims approach to identify asthma and COPD overlap syndrome patients in the United States
Bo Ding, Michael De Pietro, Bingcao Wu, Ozgur Tunceli, Ralph Turner
AB039. Pragmatic trial stepping down Flutiform® in patients maintained on high dose ICS
Anu Kemppinen, Elizabeth Gardener, Vicky Thomas, Priyanka Raju, Christina Callan, Andrew McLoughlin, Vanessa Woodhead, Adam Brady, Elizabeth F. Juniper, Peter Barnes, Omar S. Usmani, David Price
AB016. Characteristics of newly diagnosed COPD patients without maintenance treatment: a population-based study
Miriam Barrecheguren, Monica Monteagudo, Teresa Rodriguez-Blanco, Cristina Esquinas, Jaume Ferrer, Eulalia Borrell, Pere Simonet, Carl Llor, Marc Miravitlles
AB024. Influences of socio-economic status on costs of asthma under universal health coverage
Wenjia Chen, Larry D. Lynd, J. Mark FitzGerald, Mohsen Sadatsafavi
AB032. Opportunities for real-life respiratory research in Korea: the HIRA database and beyond
Job FM van Boven, Chin-Kook Rhee, Hae-Yun Park, Kwang Ha Yoo, Dong-Kyu Kim, Joan Soriano, Simon Wan Yau Ming, David Price, Hae Sim Park
AB040. Determinants of increase FeNO in individuals with suspected asthma
Maria Batsiou, Sandra Kreuzaler, Elizabeth Gardener, Dermot Ryan, Kevin Gruffydd-Jones, Mike Thomas, Roland Buhl, Jörgen Syk, Anne Copland, Daryl Freeman, Therese S. Lapperre, Clifford Godley, Ken Ohta, Tze L. Tan, Tan Ngiap Chuan, Vicky Thomas, Priyanka Raju, Mark Harris, Andrew McLoughlin, David Price
AB017. Interstitial lung disease patient diagnostic journey (intensity)
David J. Lederer, Pauline Bianchi, Jeanne Loboda, Sherry Danese, Gregory P. Cosgrove
AB025. Medication adherence: placing the ‘when’ and ‘which’ in the equation
Alexandra L. Dima, Eric van Ganse, Laurent Laforest, Marijn de Bruin, the ASTRO-LAB group
AB033. Assessing the appropriateness of pharmacological prescriptions for COPD to clinical guidelines: EPOCONSUL study
Bernardino Alcázar, Myrian Calle, Juan José Soler, José Luis López-Campos, José-Maria Rodriguez, Joan Soriano, EPOCONSUL study investigators
AB041. Effectiveness and cost impact evaluation of fluticasone propionate/formoterol compared to fluticasone propionate/salmeterol
Simon Wan Yau Ming, Iain Small, Stephanie Wolfe, John Hamil, Kevin Gruffydd-Jones, Cathal Daly, Joan B. Soriano, Liz Gardner, Derek Skinner, David Price
AB018. Improving the management of patients’ assigned COPD treatment (IMPACT): turning risk assessment into practice
Daryl Freeman, Val Gerrard, Janet Turton
AB026. Excess medical cost in patients with asthma and the role of comorbidity
Wenjia Chen, Larry D. Lynd, J. Mark FitzGerald, Carlo A. Marra, Robert Balshaw, Teresa To, Hamid Tavakoli, Mohsen Sadatsafavi, for the Canadian Respiratory Research Ne
AB034. Comparative effectiveness of prescribing similar versus dissimilar inhalers for COPD therapy
Sinthia Bosnic-Anticevich, Henry Chrystyn, Richard Costello, Myrna Dolovich, Monica Fletcher, Federico Lavorini, Roberto Rodríguez-Roisin, Dermot Ryan, Simon Wan Yau Ming, Derek Skinner, David Price
AB042. Allergy Working Group Update: the burden and management of rhinitis and rhinosinusitis in UK primary care
Wytske Fokkens, Anjan Nibber, Alison Chisholm, Peter Hellings, Derek Skinner, David Price
AB019. Longitudinal asthma management profiles: visualisation of patient histories using multiple data sources
Eric Van Ganse, Sandrine Herbage, Alexandra L. Dima, Marijn de Bruin, Nathalie Texier, Flore Jacoud, Maëva Nolin, Carole Langlois, Laurent Laforest, the ASTROLAB group
AB027. Long-acting beta-agonist in combination or separate inhaler as step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids
Steve Turner, Kathryn Richardson, Clare Murray, Mike Thomas, Elizabeth V. Hillyer, Anne Burden, David B. Price, on behalf of the Respiratory Effectivene
AB035. Use of antibiotics among patients hospitalized for exacerbations of asthma
Mihaela S. Stefan, Peter K. Lindenauer, Laura C. Feemster, Meng-Shiou Shieh, Shannon S. Carson, David H. Au, Jerry A. Krishnan
AB012. Current burden of uncontrolled asthma in the general population: the OPCRD asthma state of the Union study
Anjan Nibber, Mike Thomas, Vicky Thomas, Wim van Aalderen, Eugene Bleecker, Jonathan Campbell, Nicolas Roche, John Haughney, Eric Van Ganse, Hye-Yun Park, Chin Kook Rhee, Derek Skinner, Alison Chisholm, Job FM van Boven, Joan B. Soriano, David Price
AB020. To produce a white paper on: ‘how to develop the perfect real-time, real-world effectiveness and cost-effectiveness trial’
Jacqueline Brereton
AB028. Use of β-blockers and the risk of asthma exacerbations
Katia Verhamme, Ulrike Goditiabois, Marjolein Engelkes, Miriam Sturkenboom, Bruno Stricker, Guy Brusselle
AB036. Real-life experience of COPD patients on ease and accuracy of inhaler use: the REAL survey
Dorothy L. Keininger, David Price, Boomi Viswanad, Matthias Gasser, Susann Walda
AB013. Inappropriate asthma therapy: a tale of two countries
Anjan Nibber, Manon Belhassen, Eric Van Ganse, Dermot Ryan, Carole Langlois, Francis Appiagyei, Derek Skinner, Laurent Laforest, Joan B. Soriano, David Price
AB021. Validation of real-world, non-research thoracic CT scans for quantitative analysis of COPD
Ronald J. Dandurand, Myriam Dandurand, Raúl San José Estépar, Jean Bourbeau, David H. Eidelman
AB029. Clinical utility of a molecular diagnostic in evaluation of interstitial lung disease
Xiaoping Wu, Michael Rosenbluth, Yoonha Choi, Sherry Danese, Pauline Bianchi, Kevin Flaherty, Fernando Martinez
AB037. Drug-related costs of rhinitis in Australia: a NostraData cross-sectional study of pharmacy ​​purchases​
A. Simon Carney, David B. Price, Pete Smith, Richard Harvey, Sinthia Bosnic-Anticevich, Louise Christian, Derek Skinner, Victoria Carter, Alice M. S. Durieux


The supplement “Impact and Influence of Real-Life Respiratory Research - Abstracts from the Respiratory Effectiveness Group 2016 Summit” was commissioned by the Editorial office, Journal of Thoracic Disease without any sponsorship or funding. David B. Price served as the unpaid Guest Editor for the supplement.